Author:
Sarvaiya Vaidehi,Sadariya Kamlesh,Bhavsar Shailesh,Thaker Aswin,Modi Rakesh
Abstract
Cefpirome is fourth generation cephalosporin class of drug, which facilitates rapid penetration through the outer membrane of Gram-negative bacteria and results in potent activity against Gram-negative pathogens. As fever is one of the most common manifestations in bacterial diseases, the study was undertaken to investigate pharmacokinetics of single dose intravenous and intramuscular administrations of cefpirome (10 mg/kg of body weight) in healthy and lipopolysaccharide (LPS) induced febrile sheep and to perform PK-PD analysis using MIC values reported in previous studies and the pharmacokinetic parameters obtained in this study. Following intravenous and intramuscular administrations of cefpirome in healthy sheep, the plasma drug concentration was detected up to 12 h, while plasma drug concentration was detected up to 18 h following intravenous and intramuscular administrations in febrile sheep. Induction of febrile state significantly altered pharmacokinetic profile of cefpirome following intravenous and intramuscular administrations in sheep. Based on pharmacokinetic- pharmacodynamic integration, an optimal intramuscular dosage regimen of 10 mg/kg once daily for cefpirome in febrile sheep was predicted for targeted average MIC of ≤ 0.25 µg/mL.
Publisher
Indian Council of Agricultural Research, Directorate of Knowledge Management in Agriculture
Subject
General Veterinary,Animal Science and Zoology
Reference21 articles.
1. Agrawal A K, Singh S D and Jayachandran C. 2002. Comparative pharmacokinetics and dosage regimen of amikacin in afebrile and febrile goats. Indian Journal of Pharmacology 34: 356-60.
2. Balaban N Q, Helaine S, Lewis K, Ackermann M, Aldridge B, Andersson D I, Brynildsen M P, Bumann D, Camilli A, Collins J J, Dehio C, Fortune S, Ghigo J, Hardt W, Harms A, Heinemann M, Hung D T, Jenal U, Levin B R, Michiels J, Storz G, Tan M, Tenson T, Van Melderen L and Zinkernagel A. 2019. Definitions and guidelines for research on antibiotic persistence. Nature Reviews Microbiology 17(7): 441–48.
3. Connors K P, Kuti J L and Nicolau D P. 2013. Optimizing antibiotic pharmacodynamics for clinical practice. Pharmaceutica Analytica Acta 4(3): 1-8.
4. Corcione S, Lupia T and De Rosa F G. 2021. Novel cephalosporins in septic subjects and severe infections: Present findings and future perspective. Frontiers in Medicine 8: 617378.
5. Craig W A and Andes D R. 2015. Cephalosporins. In: Mandell, Douglas, and Bennett’s Principles and Practice of Infectious diseases. (8th Ed.). pp. 278-92. Philadelphia: Churchill Livingstone Elsevier.